Global Human Albumin Market 2016-2020

Global Human Albumin Market 2016-2020

About the Human Albumin Market

Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer's disease) are expected to enter the market during the forecast period.

The demand for albumin is high in APAC in countries like India and China. Still, the uptake of these therapeutics is less due to the lack of awareness about these products and their therapeutic uses. Thus, the awareness programs conducted by organizations such as PPTA, which includes International Plasma Awareness Week, to help increase the awareness about plasma donation and the different plasma protein therapies available, along with their potential uses, is expected to increase the uptake of these therapeutics in treating various conditions.

Technavio’s analysts forecast the global human albumin market to grow at a CAGR of 4.97% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period. The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Human Albumin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • CSL Behring
  • Grifols
  • Baxalta
  • Octapharma
  • Kedrion
Other prominent vendors
  • AADi
  • Ablynx
  • Albumedix
  • Ampio Pharmaceuticals
  • Azaya Therapeutics
  • Beijing Tiantan
  • Biotest
  • Bristol-Myers Squibb
  • Celgene
  • ConjuChem
  • GSK
  • Hebei Changshan Biochem Pharma
  • HiMedia Laboratories
  • Hualan Biological Engineering
  • InVittria
  • MedxBio
  • Merck
  • Mitsubishi Tanabe Pharma
  • NantBioScience
  • Novo Nordisk
  • Novozymes
  • Shanghai RAAS Blood Products
  • Sucampo Pharmaceuticals
  • Teva Pharmaceuticals
  • Thermo Fisher Scientific
  • Tianjin SinoBiotech & Beijing Bio-Fortune
  • Ventria Bioscience
  • Yoshitomi Pharmaceutical
Market driver
  • High demand for human albumin in China
  • For a full, detailed list, view our report
Market challenge
  • Spread of pathogenic contaminants
  • For a full, detailed list, view our report
Market trend
  • Rise in non-therapeutic applications
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Human Albumin Market 2016-2020

Technavio recognizes the following companies as the key players in the global human albumin market: CSL Behring, Grifols, Baxalta, Octapharma, and Kedrion.

Other Prominent Vendors in the market are: AADi, Ablynx, Albumedix, Ampio Pharmaceuticals, Azaya Therapeutics, Beijing Tiantan, Biotest, Bristol-Myers Squibb, Celgene, ConjuChem, GSK, Hebei Changshan Biochem Pharma, HiMedia Laboratories, Hualan Biological Engineering, InVittria, MedxBio, Merck, Mitsubishi Tanabe Pharma, NantBioScience, Novo Nordisk, Novozymes, Shanghai RAAS Blood Products, Sucampo Pharmaceuticals, Teva Pharmaceuticals, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, Ventria Bioscience, and Yoshitomi Pharmaceutical.

Commenting on the report, an analyst from Technavio’s team said: “A trend helping to propel market growth is the rise in non-therapeutic applications. Non-therapeutic applications of albumin are on a rise. Research is yet to evaluate the applications of albumin as an excipient for commercial use. Some areas where albumin can be employed are as a drug-formulating agent, an ingredient in vaccines and sealant in surgeries, and to coat medical devices and equipment. Though the current supply of albumin for non-therapeutic purposes is low, the high interest shown by the research institutes and pharmaceutical and biopharmaceutical companies in investigating the potential non-therapeutic uses of albumin is expected to drive the market.”

According to the report, a key driver is the high demand for human albumin in China. China is the largest market for albumin products. Albumin is being used as a volume replacement therapy and for treating kidney diseases, cirrhosis, and cancer. But the demand for plasma products, primarily albumin and immunoglobulins, is outstripping the supply. This is because of the stringent regulations imposed on the supply of raw materials and ban in the import of plasma products. Because of the increased demand for albumin products, the ban on import of plasma products did not include albumin

Further, the report states that one challenge that could curtail market growth is the spread of pathogenic contaminants.

Companies Mentioned

CSL Behring, Grifols, Baxalta, Octapharma, Kedrion, AADi, Ablynx, Albumedix, Ampio Pharmaceuticals, Azaya Therapeutics, Beijing Tiantan, Biotest, Bristol-Myers Squibb, Celgene, ConjuChem, GSK, Hebei Changshan Biochem Pharma, HiMedia Laboratories, Hualan Biological Engineering, InVittria, MedxBio, Merck, Mitsubishi Tanabe Pharma, NantBioScience, Novo Nordisk, Novozymes, Shanghai RAAS Blood Products, Sucampo Pharmaceuticals, Teva Pharmaceuticals, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, Ventria Bioscience, Yoshitomi Pharmaceutical.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Plasma therapeutics: An overview
    • Components of blood plasma
      • Table Blood plasma composition
      • Table Plasma proteins composition by percentage share
    • Derivation of various plasma therapeutics
      • Table Total number of plasma donations in US 2010-2014
      • Table Projected global YoY growth and fractionation capacity of manufacturing units (millions of liter/annum)
      • Table Process of derivation of AAT from plasma
  • Global plasma therapeutics market
    • Market overview
    • Market size and forecast
      • Table Global plasma therapeutics market 2015-2020 ($ billions)
      • Table Segmentation of plasma-derived products on revenue 2015
  • Plasma fractionation market
    • Overview
    • Market size and forecast
      • Table Global plasma fractionation market 2015-2020 ($ billions)
    • Market players
  • Albumin: An overview
    • Types of albumin
    • Albumin in human body
    • Clinical uses
      • Table Line of treatment of albumin in various diseases
  • Pipeline portfolio
    • Table Pipeline portfolio: Albumin-based therapeutics
  • Global albumin market
    • Table Segmentation of global albumin market
  • Market landscape
    • Global human albumin market
      • Table Global human albumin market 2015-2020 ($ billions)
      • Table Global human albumin market 2015-2020 (tons)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by application
    • Table Segmentation of human albumin market based on application
    • Replacement therapy
    • Drug formulation and delivery
    • Vaccine ingredients
    • Others
  • Geographical segmentation
    • Global human albumin market by geographical segmentation 2015-2020
      • Table Segmentation of global human albumin market based on geography 2015
      • Table Human albumin market revenue by geography 2015-2020 ($ billions)
      • Table Human albumin market by geography 2015-2020
    • Human albumin market in APAC
      • Table Human albumin market in APAC 2015-2020 ($ billions)
      • Table Albumin market in China in global albumin market 2015
    • Human albumin market in Americas
      • Table Human albumin market in Americas 2015-2020 ($ billions)
      • Table Albumin market in US 2015
    • Human albumin market in EMEA
      • Table Human albumin market in EMEA 2015-2020 ($ millions)
      • Table Global human albumin market: YoY growth and revenue based on geography 2015-2020
  • China albumin market
    • Plasma therapeutics market in China
      • Table Segmentation of various plasma products 2015
      • Table Plasma therapeutics market in China 2015-2020 ($ billions)
    • Human albumin market in China
      • Table Human albumin market in China 2015-2020 ($ billions)
      • Table Domestic and imported albumin in China 2015
  • Market drivers
    • High demand for human albumin in China
    • Exploitation of new therapeutic indications
    • Increase in production capacity
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • High cost of therapy
    • Spread of pathogenic contaminants
    • High regulations in the market
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Novel technologies for albumin-based drug development
    • Rise in non-therapeutic applications
    • Increased development of recombinant albumin
  • Vendor landscape
    • Competitive scenario
    • Market analysis 2015
    • CSL Behring
      • Table CSL Behring: Segmentation by revenue 2015
      • Table CSL Behring: YoY revenue and growth rate of albumin products 2013-2015 ($millions)
      • Table CSL Behring: Key takeaways
    • Grifols
      • Table Grifols: YoY growth rate and revenue of bioscience segment 2013-2015 ($ billions)
      • Table Grifols: Key takeaways
    • Baxalta
      • Table Baxalta: Segmentation by revenue 2015
      • Table Baxalta: YoY revenue comparison of Biotherapeutics segment 2013-2015 ($millions)
      • Table Baxalta: Geographic segmentation of BioTherapeutics 2015
      • Table Baxalta: Key takeaways
    • Octapharma
      • Table Octapharma: Key takeaways
    • Kedrion
      • Table Kedrion: Key takeaways Strategy
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook